title: Epidermal growth factor receptor inhibitors in lung cancer therapy.
abstract: Over the past decade our evolving knowledge and understanding of cancer biology has allowed rapid progression in the development of targeted cancer therapy. Improving lung cancer mortality has remained a difficult task; however, therapeutic agents directed against the epidermal growth factor receptor (EGFR) have provided physicians with a valuable new tool to integrate into multimodality therapy. EGFR inhibitors have been shown to elicit meaningful antitumor effects and quality-of-life benefits with acceptable toxicity. The rationale, utility, toxicity profile, and therapeutic strategy of EGFR-targeted therapy will be reviewed.
authors.affiliation: Division of Medical Oncology, BC Cancer Agency, Vancouver, British Columbia, Canada. jlaskin@bccancer.bc.ca
authors.forename: Janessa J
authors.initials: JJ
authors.lastname: Laskin
authors.forename: Alan B
authors.initials: AB
authors.lastname: Sandler